Radiobiological considerations for the effect by dose-rate change on radiotherapy; summary of reports in recent five years

Research output: Contribution to journalArticle

Abstract

For many years, a wide range of dose-rates have been used for brachytherapy, but there has been a move towards high dose-rate (HDR) treatment in Japan. It has been generally believed that late effects should be worse for HDR compared with low dose-rate (LDR) protocol. We report the changing situations of HDR treatment with the clinical and radiobiological considerations. When the dose of HDR treatment is matched to produce early effects equal to those of LDR treatment, if the dose responsible for late effects is less than the tumor dose by a factor more than the ratio of α/β for late effects to α/β for early effects (this ratio can be assumed about 1/2 from experimental data), then the HDR late effects will not be worse than those at LDR. This implies that if the normal tissue dose were about half that of the tumor dose, HDR would produce late effects similar to those of LDR.

Original languageEnglish
Pages (from-to)651-656
Number of pages6
JournalJapanese Journal of Clinical Radiology
Volume40
Issue number6
Publication statusPublished - 1995

Fingerprint

Radiotherapy
Brachytherapy
Therapeutics
Neoplasms
Japan

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{cba9b5e8cd864bccb16ebe92eb879d0a,
title = "Radiobiological considerations for the effect by dose-rate change on radiotherapy; summary of reports in recent five years",
abstract = "For many years, a wide range of dose-rates have been used for brachytherapy, but there has been a move towards high dose-rate (HDR) treatment in Japan. It has been generally believed that late effects should be worse for HDR compared with low dose-rate (LDR) protocol. We report the changing situations of HDR treatment with the clinical and radiobiological considerations. When the dose of HDR treatment is matched to produce early effects equal to those of LDR treatment, if the dose responsible for late effects is less than the tumor dose by a factor more than the ratio of α/β for late effects to α/β for early effects (this ratio can be assumed about 1/2 from experimental data), then the HDR late effects will not be worse than those at LDR. This implies that if the normal tissue dose were about half that of the tumor dose, HDR would produce late effects similar to those of LDR.",
author = "Naoyuki Shigematsu",
year = "1995",
language = "English",
volume = "40",
pages = "651--656",
journal = "Japanese Journal of Clinical Radiology",
issn = "0009-9252",
publisher = "Kanehara Shuppan Co. Ltd",
number = "6",

}

TY - JOUR

T1 - Radiobiological considerations for the effect by dose-rate change on radiotherapy; summary of reports in recent five years

AU - Shigematsu, Naoyuki

PY - 1995

Y1 - 1995

N2 - For many years, a wide range of dose-rates have been used for brachytherapy, but there has been a move towards high dose-rate (HDR) treatment in Japan. It has been generally believed that late effects should be worse for HDR compared with low dose-rate (LDR) protocol. We report the changing situations of HDR treatment with the clinical and radiobiological considerations. When the dose of HDR treatment is matched to produce early effects equal to those of LDR treatment, if the dose responsible for late effects is less than the tumor dose by a factor more than the ratio of α/β for late effects to α/β for early effects (this ratio can be assumed about 1/2 from experimental data), then the HDR late effects will not be worse than those at LDR. This implies that if the normal tissue dose were about half that of the tumor dose, HDR would produce late effects similar to those of LDR.

AB - For many years, a wide range of dose-rates have been used for brachytherapy, but there has been a move towards high dose-rate (HDR) treatment in Japan. It has been generally believed that late effects should be worse for HDR compared with low dose-rate (LDR) protocol. We report the changing situations of HDR treatment with the clinical and radiobiological considerations. When the dose of HDR treatment is matched to produce early effects equal to those of LDR treatment, if the dose responsible for late effects is less than the tumor dose by a factor more than the ratio of α/β for late effects to α/β for early effects (this ratio can be assumed about 1/2 from experimental data), then the HDR late effects will not be worse than those at LDR. This implies that if the normal tissue dose were about half that of the tumor dose, HDR would produce late effects similar to those of LDR.

UR - http://www.scopus.com/inward/record.url?scp=0029010183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029010183&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029010183

VL - 40

SP - 651

EP - 656

JO - Japanese Journal of Clinical Radiology

JF - Japanese Journal of Clinical Radiology

SN - 0009-9252

IS - 6

ER -